Generic Zyflo CR Availability
See also: Generic Zyflo
ZYFLO CR (zileuton - tablet, extended release;oral)
Manufacturer: CHIESI USA INC
Approval date: May 30, 2007
Strength(s): 600MG [RLD]
Has a generic version of Zyflo CR been approved?
No. There is currently no therapeutically equivalent version of Zyflo CR available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyflo CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pharmaceutical tablet capable of liberating one or more drugs at different release rates
Issued: February 6, 2001
Inventor(s): Conte; Ubaldo & LaManna; Aldo & Maggi; Lauretta
Assignee(s): Jagotec AG
Pharmaceutical tablet consisting of a first layer containing one or more drugs with immediate or controlled release formulation, a second layer containing one or more drugs, either equal to or different from the first layer, with slow release formulation, and a low-permeability barrier-type layer coating said second layer or, alternatively, placed between the first and second layer and, if necessary, containing a drug.Patent expiration dates:
- September 21, 2013✓
- September 21, 2013
- Zyflo CR extended-release tablets Consumer Information (Wolters Kluwer)
- Zyflo CR Consumer Information (Cerner Multum)
- Zyflo CR Advanced Consumer Information (Micromedex®)
- Zileuton Consumer Information (Wolters Kluwer)
- Zileuton extended-release tablets Consumer Information (Wolters Kluwer)
- Zileuton Consumer Information (Cerner Multum)
- Zileuton Advanced Consumer Information (Micromedex®)
- Zileuton AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|